Global Immunoglobulin Market

Immunoglobulin Market Size, Share, Growth Analysis, By Type(Immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG)), By Application(Primary immunodeficiency diseases, autoimmune disorders, infectious diseases, hypogammaglobulinemia), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35G2149 | Region: Global | Published Date: April, 2024
Pages: 219 | Tables: 64 | Figures: 75

Immunoglobulin Market News

  • In February 2023, Kedrion Biopharma, a biopharmaceutical company specializing in plasma-derived products, announced the completion of a Phase 3 clinical trial for its novel subcutaneous immunoglobulin (SCIG) therapy, KEDRABIO. The trial demonstrated the safety and efficacy of KEDRABIO in patients with primary immunodeficiencies, offering a potential alternative treatment option.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Immunoglobulin Market size was valued at USD 15.05 billion in 2022 and is poised to grow from USD 16.39 billion in 2023 to USD 32.42 billion by 2031, growing at a CAGR of 8.90% during the forecast period (2024-2031).

The Immunoglobulin market is characterized by a mix of established companies and emerging players. Market participants are focusing on research and development activities to enhance the efficiency and performance of Immunoglobulins. Additionally, strategic collaborations, partnerships, and mergers and acquisitions are prevalent strategies adopted by companies to expand their market presence. The competitive environment is further influenced by factors such as technological advancements, government regulations, and the ability to provide cost-effective and sustainable solutions. 'CSL Behring (Australia)', 'Grifols (Spain)', 'Takeda Pharmaceutical Company Limited (Japan)', 'Octapharma AG (Switzerland)', 'Kedrion Biopharma (Italy)', 'Shire (Ireland)', 'Biotest AG (Germany)', 'China Biologic Products Holdings, Inc. (China)', 'Sanquin (Netherlands)', 'LFB Group (France)', 'Bio Products Laboratory (UK)', 'ADMA Biologics, Inc. (USA)', 'GC Pharma (South Korea)', 'Bharat Serums and Vaccines Ltd. (India)', 'Shanghai RAAS Blood Products Co., Ltd. (China)', 'Grifols Biologicals Inc. (USA)', 'BPL Plasma, Inc. (USA)', 'Green Cross Corporation (South Korea)', 'Beijing Tiantan Biological Products Corporation Limited (China)', 'Emergent BioSolutions (USA)'

One key driver of the Immunoglobulin market is the increasing prevalence of immunological disorders. Immunoglobulins are crucial in the treatment of various conditions, including primary immunodeficiency diseases, autoimmune disorders, and infectious diseases. The rising incidence of these disorders, coupled with improved diagnostic capabilities and awareness, has fuelled the demand for Immunoglobulin therapies. Factors such as genetic predisposition, environmental factors, and lifestyle changes contribute to the growing prevalence of immunological disorders globally. Additionally, advancements in healthcare infrastructure, increased access to healthcare services, and rising healthcare expenditure further support the market growth.

One key market trend in the Immunoglobulin market is the increasing adoption of intravenous immunoglobulin (IVIG) therapy. IVIG therapy involves the administration of Immunoglobulin intravenously to patients with immunodeficiency disorders, autoimmune diseases, and certain neurological conditions. The demand for IVIG therapy is growing due to its effectiveness in treating various medical conditions and the expanding awareness of its benefits among healthcare providers and patients. Factors such as advancements in production methods, improved product safety, and expanded indications for IVIG therapy are driving its adoption. Additionally, the rising prevalence of immunological disorders and the growing geriatric population contribute to the increasing demand for Immunoglobulin products and IVIG therapy.

One dominant region in the Immunoglobulin market is North America. North America holds a significant share in the market due to several factors. The region has a well-established healthcare infrastructure, advanced research facilities, and a high prevalence of autoimmune and immunodeficiency disorders. Additionally, favorable reimbursement policies and government initiatives to promote immunization and healthcare access further contribute to the dominance of North America in the Immunoglobulin market. The presence of major pharmaceutical companies and biotech firms in the region also plays a crucial role in driving market growth.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Immunoglobulin Market

Report ID: SQMIG35G2149

$5,300
BUY NOW GET FREE SAMPLE